Pro-algesic versus analgesic actions of immune cells

Current Opinion in Anaesthesiology

Volumn 16, Issue 5, 2003, Pages 527-533

  Rittner, Heike L ^a   Brack, Alexander ^a   Stein, Christoph ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Analgesia; Hyperalgesia; Immune cells; Opioid peptides

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADENOSINE TRIPHOSPHATE; ANALGESIC AGENT; ANANDAMIDE; ANTIINFLAMMATORY AGENT; BRADYKININ; CANNABINOID; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; MORPHINE; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; OPIATE PEPTIDE; PALMIDROL; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SOMATOSTATIN;

ANALGESIA; CIRCULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MEDIATOR RELEASE; NERVE ENDING; NONHUMAN; PAIN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW; SENSORY NERVE; SIDE EFFECT;

EID: 0142061612     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200310000-00014     Document Type: Review

References (77)

1. Julius D Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413:203-210.
2. Merskey H, Bogduk N. Pain terminology. In: Merskey H, Bogduk N, editors. Classification of chronic pain. IASP task force on taxonomy. Seattle: IASP Press; 1994. pp. 209-214.
3. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci 2002; 5 (Suppl):1062-1067. This is a complete discussion of central and peripheral aspects of different types of pain including inflammatory pain.
4. Svensson CI, Yaksh TL. The spinal phospholipase-cyclooxygenase- prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 2002; 42:553-583.
5. Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A 1999; 96:7723-7730.
6. Cunha FQ, Ferreira SH. Peripheral hyperalgesic cytokines. Adv Exp Med Biol 2003; 521:22-39.
7. Cunha FQ, Poole S, Lorenzetti BB, et al. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 1992; 107:660-664.
8. Sachs D, Cunha FQ, Poole S, et al. Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 2002; 96:89-97. This interesting study demonstrated not only acute but also persistent hyperalgesia to cytokines after repetitive injection reflecting the inflammatory situation in vivo.
9. Opree A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 2000; 20:6289-6293.
10. Oh SB, Tran PB, Gillard SE, et al. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001; 21:5027-5035.
11. Lorenzetti BB, Veiga FH, Canetti CA, et al. CINC-1 mediates the sympathetic component of inflammatory mechanical hypersensitivitiy in rats. Eur Cytokine Netw 2002; 13:456-461.
12. Eide FF, Lowenstein DH, Reichardt LF. Neurotrophins and their receptors: current concepts and implications for neurologic disease. Exp Neurol 1993; 12:200-214.
13. Manni L, Aloe L. Role of IL-1 beta and TNF-alpha in the regulation of NGF in experimentally induced arthritis in mice. Rheumatol Int 1998; 18:97-102.
14. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002; 66:243-256. These authors present an elegant outline of recent insights into the role of endocannabinoids in pain.
15. Chuang HH, Prescott ED, Kong H, et al. Bradykinin and nerve growth factor release the capsaicin receptor from Ptdlns(4,5)P2-mediated inhibition. Nature 2001; 411:957-962.
16. Ji RR, Samad TA, Jin SX, et al. p38 Mapk activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002; 36:57-68. This excellent paper unravels in detail the intracellular mechanism of inflammatory heat hypersensitivity in response to NGF.
17. Mamet J, Baron A, Lazdunski M, et al. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci 2002; 22:10662-10670. This interesting study linked increased acid-sensing ion channel expression in inflammation to two proinflammatory mediators: NGF and serotonin.
18. Voilley N, de Weille J, Mamet J, et al. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci 2001; 21:8026-8033.
19. Calixto JB, Cabrini DA, Ferreira J, et al. Kinins in pain and inflammation. Pain 2000; 87:1-5.
20. Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev 2003; 55:1-20. This is an elegant discussion of recent developments in peripheral analgesics.
21. Hwang SW, Cho H, Kwak J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 2000; 97:6155-6160.
22. Romsing J, Moiniche S, Ostergaard D, et al. Local infiltration with NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action. Acta Anaesthesiol Scand 2000; 44:672-683.
23. Omote K, Kawamata T, Nakayama Y, et al. The effects of peripheral administration of a novel selective antagonist for prostaglandin E receptor subtype EP(1), ONO-8711, in a rat model of postoperative pain. Anesth Analg 2001; 92:233-238.
24. Sarkar S, Hobson AR, Hughes A, et al. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 2003; 124:18-25. This study provided the first evidence of the effectiveness of local application of prostaglandin receptor antagonists against acid induced pain in human volunteers.
25. Ramer MS, Bradbury EJ, McMahon SB. Nerve growth factor induces P2X(3) expression in sensory neurons. J Neurochem 2001; 77:864-875.
26. Hamilton SG, Warburton J, Bhattacharjee A, et al. ATP in human skin elicits a dose-related pain response which is potentiated under conditions of hyperalgesia. Brain 2000; 123 (Pt 6):1238-1246.
27. Hamilton SG, Wade A, McMahon SB. The effects of inflammation and inflammatory mediators on nociceptive behaviour induced by ATP analogues in the rat. Br J Pharmacol 1999; 126:326-332.
28. Souslova V, Cesare P, Ding Y, et al. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature 2000; 407:1015-1017.
29. Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 2000; 407:1011-1015.
30. Dell'Antonio G, Quattrini A, Cin ED, et al. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum 2002; 46:3378-3385. The authors describe a novel approach using local application of an ATP antagonist for long lasting analgesia in arthritis.
31. Dell'Antonio G, Quattrini A, Dal Cin E, et al. Antinociceptive effect of a new P(2Z)/P2X7 antagonist, oxidized ATP, in arthritic rats. Neurosci Lett 2002; 327:87-90.
32. Levine JD, Gooding J, Donatoni P, et al. The role of the polymorphonuclear leukocyte in hyperalgesia. J Neurosci 1985; 5:3025-3029.
33. Perkins NM, Tracey DJ. Hyperalgesia due to nerve injury: role of neutrophils. Neuroscience 2000; 101:745-757.
34. Ribeiro RA, Vale ML, Thomazzi SM, et al. Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. Eur J Pharmacol 2000; 387:111-118.
35. Carlton SM, Du J, Davidson E, et al. Somatostatin receptors on peripheral primary afferent terminals: inhibition of sensitized nociceptors. Pain 2001; 90:233-244.
36. Heppelmann B, Pawlak M. Inhibitory effect of somatostatin on the mechanosensitivity of articular afferents in normal and inflamed knee joints of the rat. Pain 1997; 73:377-382.
37. Fioravanti A, Govoni M, La Montagna G, et al. Somatostatin 14 and joint inflammation: evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis. Drugs Exp Clin Res 1995; 21:97-103.
38. Carlton SM, Du J, Zhou S, et al. Tonic control of peripheral cutaneous nociceptors by somatostatin receptors. J Neurosci 2001; 21:4042-4049.
39. Paran D, Elkayam O, Mayo A, et al. A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis. Ann Rheum Dis 2001; 60:888-891.
40. Blum AM, Elliott DE, Metwali A, et al. Substance P regulates somatostatin expression in inflammation. J Immunol 1998; 161:6316-6322.
41. Bisogno T, Maurelli S, Melck D, et al. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 1997; 272:3315-3323.
42. Berdyshev EV, Schmid PC, Krebsbach RJ, et al. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB J 2001; 15:2171-2178.
43. Smith FL, Fujimori K, Lowe J, et al. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 1998; 60:183-191.
44. Zimmer A, Zimmer AM, Hohmann AG, et al. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999; 96:5780-5785.
45. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283:401-404.
46. Lorenzetti BB, Poole S, Veiga FH, et al. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-13. Eur Cytokine Netw 2001; 12:260-267.
47. Cunha FQ, Poole S, Lorenzetli BB, et al. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. Br J Pharmacol 1999; 126:45-50.
48. Cunha JM, Cunha FQ, Poole S, et al. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol 2000; 130:1418-1424.
49. Poole S, Cunha FQ, Selkirk S, et al. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br J Pharmacol 1995; 115:684-688.
50. Vale ML, Marques JB, Moreira CA, et al. Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. J Pharmacol Exp Ther 2003; 304:102-108.
51. Ji RR, Zhang Q, Law PY, et al. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J Neurosci 1995; 15:8156-8166.
52. Schäfer MK, Bette M, Romeo H, et al. Localization of kappa-opioid receptor mRNA in neuronal subpopulations of rat sensory ganglia and spinal cord. Neurosci Lett 1994; 167:137-140.
53. Stein C. Opioid receptors on peripheral sensory neurons. Adv Exp Med Biol 2003; 521:69-76.
54. Machelska H, Schopohl JK, Mousa SA, et al. Different mechanisms of intrinsic pain inhibition in early and late inflammation. J Neuroimmunol (in press).
55. Mousa SA, Zhang Q, Sitte N, et al. beta-Endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. J Neuroimmunol 2001; 115:71-78.
56. Zöllner C, Shaqura MA, Bopaiah CP, et al. Painful inflammation induced increase in μ opioid receptor binding and G-protein coupling in primary afferent neurons. Mol Pharm 2003 (in press).
57. Hassan AH, Ableitner A, Stein C, et al. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience 1993; 55:185-195.
58. Cabot PJ, Carter L, Gaiddon C, et al. Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest 1997; 100:142-148.
59. Cabot PJ, Carter L, Schafer M, et al. Methionine- enkephalin- and Dynorphin A-release from immune cells and control of inflammatory pain. Pain 2001; 93:207-212.
60. Osaba G, Kovacs P, Pallinger E. Beta-endorphin in granulocytes. Cell Biol Int 2002; 26:741-743.
61. Mousa SA, Machelska H, Schafer M, et al. Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain. J Neuroimmunol 2002; 126:5-15.
62. Vindrola O, Padros MR, Sterin-Prync A, et al. Proenkephalin system in human polymorphonuclear cells. Production and release of a novel 1.0-kD peptide derived from synenkephalin. J Clin Invest 1990; 86:531-537.
63. Smith EM. Opioid peptides in immune cells. Adv Exp Med Biol 2003; 521:51-68.
64. Przewlocki R, Hassan AH, Lason W, et al. Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. Neuroscience 1992; 48:491-500.
65. Rittner HL, Brack A, Machelska H, et al. Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology 2001; 95:500-508.
66. Machelska H, Cabot PJ, Mousa SA, et al. Pain control in inflammation governed by selectins. Nat Med 1998; 4:1425-1428.
67. Machelska H, Mousa SA, Brack A, et al. Opioid control of inflammatory pain regulated by intercellular adhesion molecule-1. J Neurosci 2002; 22:5588-5596. This elegant study demonstrates an impact of anti-intercellular adhesion molecule treatment on endogenous analgesia. This might have the consequence of impaired analgesia when using anti-intercellular adhesion molecule for treatment of autoimmune or other inflammatory diseases.
68. Schmitt TK, Mousa SA, Brack A, et al. Modulation of peripheral endogenous opioid analgesia by central afferent blockade. Anesthesiology 2003; 98:195-202. This paper outlines the impact of sufficient central analgesia by intrathecal morphine on endogenous peripheral analgesia providing a link between animal studies and clinical usage of epidural anaesthesia for postoperative pain treatment.
69. Schäfer M, Mousa SA, Zhang Q, et al. Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Proc Natl Acad Sci USA 1996; 93:6096-6100.
70. Radulovic M, Dautzenberg FM, Sydow S, et al. Corticotropin-releasing factor receptor 1 in mouse spleen: expression after immune stimulation and identification of receptor-bearing cells. J Immunol 1999; 162:3013-3021.
71. Czlonkowski A, Stein C, Herz A. Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur J Pharmacol 1993; 242:229-235.
72. Schäfer M, Carter L, Stein C. Interleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci U S A 1994; 91:4219-4223.
73. Schäfer M, Mousa SA, Stein C. Corticotropin-releasing factor in antinociception and inflammation. Eur J Pharmacol 1997; 323:1-10.
74. Stein C, Hassan AH, Przewlocki R, et al. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci U S A 1990; 87:5935-5939.
75. Stein C, Gramsch C, Herz A. Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. J Neurosci 1990; 10:1292-1298.
76. Kalso E, Smith L, McQuay HJ, et al. No pain, no gain: clinical excellence and scientific rigour: lessons learned from IA morphine. Pain 2002; 98:269-275. This outstanding review examines in detail the effectiveness of clinical studies using local opioids.
77. Stein C, Hassan AH, Lehrberger K, et al. Local analgesic effect of endogenous opioid peptides. Lancet 1993; 342:321-324.